BioAtla shares surge 10.78% after-hours following regulatory update on ozuriftamab vedotin clinical development post-FDA meeting.

BioAtla (BCAB) surged 10.78% in after-hours trading following Nasdaq’s February 6, 2026, delisting decision due to the company’s failure to meet the $1.00 bid price rule and $2.5 million stockholders’ equity requirement. The stock’s upward movement coincided with the company’s immediate appeal to the Nasdaq Listing and Hearing Review Council and a request for a suspension stay ahead of the February 10, 2026, trading halt. While delisting typically signals bearish sentiment, the sharp after-hours rally may reflect speculative positioning on a potential stay or favorable review outcome, despite the broader negative implications of OTC quotation. The move underscores market focus on regulatory developments and short-term uncertainty surrounding the company’s listing status.